Literature DB >> 30670823

Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia.

Lin-Pierre Zhao1, Flore Sicre De Fontbrune1, Adrien Contejean2, Julie Abraham3, Louis Terriou4, Cécile Chabrot5, Amandine Charbonnier6, Etienne Lengline1, Gérard Socié1,7,8, Régis Peffault de Latour9,10.   

Abstract

Entities:  

Year:  2019        PMID： 30670823     DOI： 10.1038/s41409-019-0452-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  6 in total

Review 1.  Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.

Authors:  Cindy E Neunert; Melissa J Rose
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature.

Authors:  Nicolas Gendron; Flore Sicre de Fontbrune; Alice Guyard; Jehane Fadlallah; Sylvain Chantepie; Maud D'Aveni; Ronan Le Calloch; Alice Garnier; Marie-Anne Couturier; Véronique Morel; Claire Bernard; Louis Terriou; Estibaliz Lazaro; Gérard Socié; Régis Peffault de Latour
Journal:  Haematologica       Date:  2019-11-14       Impact factor: 9.941

Review 3.  Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Leyre Bento; Mariana Canaro; José María Bastida; Antonia Sampol
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

Review 4.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

5.  [How I treat refractory sever aplastic anemia].

Authors:  F K Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14

6.  Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.

Authors:  Jun Ho Jang; Yoshiaki Tomiyama; Koji Miyazaki; Koji Nagafuji; Kensuke Usuki; Nobuhiko Uoshima; Tomoaki Fujisaki; Hiroshi Kosugi; Itaru Matsumura; Ko Sasaki; Masahiro Kizaki; Masashi Sawa; Michihiro Hidaka; Naoki Kobayashi; Satoshi Ichikawa; Yuji Yonemura; Kouki Enokitani; Akira Matsuda; Keiya Ozawa; Kinuko Mitani; Jong Wook Lee; Shinji Nakao
Journal:  Br J Haematol       Date:  2020-11-05       Impact factor: 6.998
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.